Adult Vaccines are an essential component of preventive healthcare, offering protection against a range of infectious diseases that can pose serious risks to adults' health and well-being. While often overshadowed by childhood vaccination programs, adult immunization is equally crucial for maintaining individual health and preventing the spread of contagious illnesses within communities. Influenza, commonly known as the flu, is a prime example of a vaccine-preventable disease that affects millions of adults worldwide each year. Annual flu vaccination is recommended for all adults, particularly those at higher risk of complications, such as older adults, pregnant women, and individuals with chronic health conditions.
Another important adult vaccine is the tetanus, diphtheria, and pertussis (Tdap) vaccine. Tetanus, a bacterial infection that affects the nervous system, can be transmitted through wounds or cuts and can lead to severe muscle spasms and respiratory failure. The Tdap vaccine provides protection against tetanus, diphtheria, and pertussis (whooping cough) and is recommended for adults who have not received a Tdap vaccine previously. Human papillomavirus (HPV) vaccine is another critical immunization for adults, particularly for those who may not have been vaccinated during adolescence. Vaccination against HPV can help prevent these cancers and is recommended for adults up to age 45.
Despite the clear benefits of adult vaccination, coverage rates remain suboptimal. Barriers to vaccination include lack of awareness, limited access to healthcare services, and vaccine hesitancy. Public health efforts are needed to increase awareness of the importance of adult immunization, improve access to vaccines, and address misconceptions about vaccine safety and efficacy.
Title : A universal AI design framework and brokerage platform for democratised manufacturing of mRNA therapeutics
Duccio Medini, BioForge, United States
Title : Personalized and Precision Medicine (PPM) via biodesign-driven translational applications and upgraded business modeling to secure the human biosafety: The next-step vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Development of VSV-vector based vaccine against H5N1 avian influenza by targeting both H5N1 hemagglutinin and matrix protein 2
Zhujun Ao, University of Manitoba, Canada
Title : A novel responsive microneedle platform for reliable drug and vaccine delivery
Huanhuan Li, Queen’s University Belfast, United Kingdom
Title : Emerging nanovaccine strategies for enhanced immune targeting and vaccine performance
Aysel Sadayli, V.Y. Axundov Scientific-Research Institute of Medical Prophylaxis, Azerbaijan
Title : The promise of nanotechnology in Personalized & Precision Medicine: Nano-driven precision vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Reaching zero-dose children through adaptive immunization strategies in security-compromised areas of Zamfara State, Nigeria
Attahir Abubakar, Ahmadu Bello University, Nigeria
Title : Comparative efficacy of different H9N2 avian influenza virus inactivated vaccines using some commercially available adjuvants for superior control in broilers
Ayman H M El Deeb, Cairo University, Egypt
Title : Structure-based design and development of next-generation Respiratory Syncytial Virus (RSV) vaccine
Lei Chen, Yikang Biotech Suzhou Co., Ltd, China
Title : Unmasking urban immunization inequities: A cross-sectional LQAS analysis of zero-dose drivers in slum and non-slum settings of Uttar Pradesh, India
Ashish Kumar Maurya, John Snow India, India